Cannan C R, Nishimura R A, Reeder G S, Ilstrup D R, Larson D R, Holmes D R, Tajik A J
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Am Coll Cardiol. 1997 Jan;29(1):175-80. doi: 10.1016/s0735-1097(96)00422-6.
This study was undertaken to determine whether the presence of calcium in the mitral valve commissures, as demonstrated echocardiographically, could predict outcome and to compare this with an established echocardiographic scoring system.
Percutaneous mitral balloon valvotomy is an effective form of treatment for mitral valve stenosis. It is important to identify patients who would benefit from this procedure. Commissural splitting is the dominant mechanism by which mitral valve stenosis is relieved by this technique, and thus commissural morphology may predict outcome.
One hundred forty-nine consecutive patients who underwent percutaneous mitral balloon valvotomy at the Mayo Clinic were evaluated retrospectively. The morphology of the mitral valve apparatus on the baseline echocardiograms was scored in blinded manner using a semiquantitative grading system of leaflet thickening, mobility, calcification and subvalvular thickening (Abascal score). Additionally, each of the medial and lateral commissures was graded for the presence or absence of calcification. End points were death, New York Heart Association functional class, repeat percutaneous mitral balloon valvotomy and mitral valve replacement at follow-up.
The mean follow-up period was 1.8 years (maximum 7.9 years). Univariate predictors of death and all events combined included age, the use of a double-balloon technique, the presence of calcium in a commissure and the Abascal score, as continuous variables. Patients with an Abascal score < or = 8 showed a trend toward improved survival at 36 months free of death, repeat percutaneous mitral balloon valvotomy or mitral valve replacement (78 +/- 6% vs. 67 +/- 8%, p = 0.07) and free of all events combined (75 +/- 6% vs. 64 +/- 8%, p = 0.07) versus those patients with a score > 8. However, survival at 36 months free of death, repeat percutaneous mitral balloon valvotomy or mitral valve replacement (86 +/- 4% vs. 40 +/- 4%) and free of all events combined (82 +/- 5% vs. 38 +/- 10%) at follow-up was significantly different between patients without commissural calcium and those with commissural calcium (p < 0.001). In a Cox regression model with Abascal score and commissural calcium and their interaction, calcification emerged as the only significant variable (p < 0.01).
The presence of commissural calcium is a strong predictor of outcome after percutaneous mitral balloon valvotomy. Patients with evidence of calcium in a commissure have a lower survival rate and a higher incidence of mitral valve replacement and all end points combined. Thus, the simple presence or absence of commissural calcification assessed by two-dimensional echocardiography can be used to predict outcome.
本研究旨在确定经超声心动图显示的二尖瓣联合处钙化情况是否能够预测经皮二尖瓣球囊成形术的治疗结果,并将其与已确立的超声心动图评分系统进行比较。
经皮二尖瓣球囊成形术是二尖瓣狭窄的一种有效治疗方式。识别能从此手术中获益的患者很重要。联合处分离是该技术缓解二尖瓣狭窄的主要机制,因此联合处形态可能预测治疗结果。
对梅奥诊所连续149例行经皮二尖瓣球囊成形术的患者进行回顾性评估。使用关于瓣叶增厚、活动度、钙化及瓣下增厚的半定量分级系统(阿巴斯卡尔评分),以盲法对基线超声心动图上二尖瓣装置的形态进行评分。此外,对内侧和外侧联合处的钙化情况进行分级。终点指标为随访时的死亡、纽约心脏协会心功能分级、再次经皮二尖瓣球囊成形术及二尖瓣置换术。
平均随访期为1.8年(最长7.9年)。死亡及所有事件总发生率的单因素预测因素包括年龄、双球囊技术的使用、联合处钙化情况及阿巴斯卡尔评分(作为连续变量)。阿巴斯卡尔评分≤8分的患者在36个月时无死亡、再次经皮二尖瓣球囊成形术或二尖瓣置换术的生存率有改善趋势(78±6% 对 67±8%,p = 0.07),且无所有联合事件的生存率也有改善趋势(75±6% 对 64±8%,p = 0.07),优于评分>8分的患者。然而,随访时无联合处钙化的患者与有联合处钙化的患者在36个月时无死亡、再次经皮二尖瓣球囊成形术或二尖瓣置换术的生存率(86±4% 对 40±4%)及无所有联合事件的生存率(82±5% 对 38±10%)有显著差异(p<0.001)。在包含阿巴斯卡尔评分、联合处钙化及其交互作用的Cox回归模型中,钙化是唯一的显著变量(p<0.01)。
联合处钙化是经皮二尖瓣球囊成形术后治疗结果的有力预测指标。有联合处钙化证据的患者生存率较低,二尖瓣置换术及所有终点事件的发生率较高。因此,通过二维超声心动图评估联合处钙化的有无可用于预测治疗结果。